Sumifilam

Interim results from IGC Pharma's Phase 2 CALMA trial show IGC-AD1 reduced sleep disturbances by 71% at week 2 (p=.012) and 78% at week 6 (p=.02) compared to placebo in Alzheimer's patients.

Biopharma companies continue to announce layoffs in 2025, driven by strategic realignments, pipeline reprioritizations, and challenging financial conditions.

Sarepta Therapeutics has submitted SRP-9001 (delandistrogene moxeparvovec) to the FDA for accelerated approval to treat ambulatory Duchenne muscular dystrophy (DMD) patients.

Cassava Sciences is reducing its workforce by approximately 33% as part of cost-saving measures following Phase 3 trial results.

A class action lawsuit has been filed against Cassava Sciences, alleging securities fraud related to its Alzheimer's drug candidate, simufilam.